Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 12 04:00PM ET
53.77
Dollar change
+0.23
Percentage change
0.43
%
Index- P/E- EPS (ttm)-1.29 Insider Own16.22% Shs Outstand63.05M Perf Week0.50%
Market Cap3.44B Forward P/E- EPS next Y-2.67 Insider Trans-17.32% Shs Float52.84M Perf Month3.62%
Income-80.77M PEG- EPS next Q-0.60 Inst Own95.19% Short Float15.14% Perf Quarter5.14%
Sales0.00M P/S- EPS this Y-141.19% Inst Trans-2.09% Short Ratio26.42 Perf Half Y25.90%
Book/sh7.74 P/B6.94 EPS next Y-51.65% ROA-15.86% Short Interest8.00M Perf Year-3.45%
Cash/sh7.73 P/C6.96 EPS next 5Y- ROE-17.69% 52W Range37.55 - 64.98 Perf YTD-10.96%
Dividend Est.- P/FCF- EPS past 5Y- ROI-16.48% 52W High-17.25% Beta1.31
Dividend TTM- Quick Ratio25.51 Sales past 5Y0.00% Gross Margin- 52W Low43.20% ATR (14)2.29
Dividend Ex-Date- Current Ratio25.51 EPS Y/Y TTM-36.77% Oper. Margin- RSI (14)54.94 Volatility3.33% 4.62%
Employees50 Debt/Eq0.01 Sales Y/Y TTM- Profit Margin- Recom1.27 Target Price76.69
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q-219.53% Payout- Rel Volume0.46 Prev Close53.54
Sales Surprise- EPS Surprise-28.59% Sales Q/Q- EarningsNov 07 BMO Avg Volume302.69K Price53.77
SMA202.18% SMA506.45% SMA20015.47% Trades Volume137,923 Change0.43%
Date Action Analyst Rating Change Price Target Change
Nov-05-24Resumed Wedbush Outperform $92 → $73
Aug-26-24Downgrade Wolfe Research Outperform → Peer Perform
Jun-25-24Initiated Oppenheimer Outperform $104
Apr-02-24Initiated Goldman Neutral $62
Feb-15-24Initiated Wolfe Research Outperform $77
Dec-08-23Initiated Citigroup Buy $72
Nov-02-23Initiated Stifel Buy $74
Sep-14-23Downgrade Bryan Garnier Buy → Neutral
Aug-31-23Initiated Needham Buy $76
Jun-15-23Initiated Barclays Equal Weight $28
Nov-13-24 08:00AM
Nov-07-24 07:00AM
Oct-08-24 09:11PM
Sep-24-24 11:55PM
Sep-23-24 02:44AM
07:00AM Loading…
Sep-09-24 07:00AM
Aug-27-24 08:21PM
Aug-07-24 08:00AM
Jun-10-24 08:00AM
May-16-24 08:00AM
May-07-24 09:02PM
01:53PM
10:15AM
08:00AM
Apr-10-24 07:00AM
04:25PM Loading…
Mar-11-24 04:25PM
Mar-10-24 12:00PM
Mar-04-24 08:00AM
Mar-01-24 12:38AM
Feb-29-24 08:00AM
Feb-26-24 08:00AM
Feb-20-24 11:44PM
Jan-11-24 09:55AM
Jan-10-24 08:42AM
Dec-22-23 03:01PM
Nov-14-23 12:13PM
08:00AM
Nov-06-23 04:03PM
09:46AM
Nov-05-23 11:00AM
10:33AM Loading…
Oct-26-23 10:33AM
Oct-20-23 01:22PM
Oct-16-23 04:30PM
04:04PM
10:41AM
Oct-15-23 09:03AM
Oct-11-23 10:15AM
Oct-04-23 07:01AM
Sep-27-23 09:24PM
Sep-18-23 05:09PM
Sep-13-23 09:45AM
Sep-12-23 04:07PM
11:40AM
Sep-06-23 07:00AM
Sep-01-23 02:00PM
11:30AM
Aug-31-23 09:53AM
08:30AM
Aug-16-23 03:12PM
Aug-15-23 07:00AM
Aug-10-23 07:00AM
Jul-25-23 08:00AM
Jul-14-23 03:38PM
Jul-03-23 09:45AM
Jun-29-23 02:41PM
Jun-28-23 05:00AM
Jun-27-23 06:56PM
Jun-26-23 04:07PM
04:01PM
02:36PM
09:01AM
Jun-25-23 09:00AM
May-26-23 08:50AM
May-14-23 09:43AM
May-12-23 07:45AM
May-11-23 08:32AM
May-10-23 08:50AM
May-03-23 06:45AM
Apr-24-23 08:50AM
Apr-19-23 08:16AM
Apr-05-23 12:00PM
Mar-20-23 07:45AM
Feb-14-23 01:02PM
Feb-02-23 08:00AM
Dec-14-22 08:00AM
Nov-14-22 08:00AM
Sep-26-22 10:57AM
08:00AM
Jul-26-22 08:00AM
Jul-25-22 10:11AM
May-12-22 07:00AM
Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BVF PARTNERS L P/ILDirectorOct 04 '24Sale50.002,000,000100,003,2001,287,768Oct 08 06:50 PM
Sturge SimonDirectorOct 04 '24Sale53.72171,0009,186,120171,980Oct 08 04:01 PM
Santos da Silva JorgeChief Executive OfficerFeb 27 '24Sale55.0062,8103,454,5503,043,619Feb 29 07:56 PM
Santos da Silva JorgeChief Executive OfficerFeb 28 '24Sale55.0056,0653,083,5752,987,554Feb 29 07:56 PM
Santos da Silva JorgeChief Executive OfficerFeb 29 '24Sale55.894,740264,9192,982,814Feb 29 07:56 PM
Reich KristianChief Scientific OfficerFeb 28 '24Sale55.0031,9101,755,0502,925,573Feb 29 07:53 PM
Reich KristianChief Scientific OfficerFeb 27 '24Sale55.0029,4911,622,0052,957,483Feb 29 07:53 PM
Reich KristianChief Scientific OfficerFeb 27 '24Sale55.0029,4311,618,70570,071Feb 29 07:53 PM
Reich KristianChief Scientific OfficerFeb 28 '24Sale55.0028,0901,544,95041,981Feb 29 07:53 PM
Santos da Silva JorgeChief Executive OfficerFeb 21 '24Sale55.271,12562,1793,106,429Feb 23 04:48 PM
Reich KristianChief Scientific OfficerFeb 20 '24Sale57.4510,000574,5002,987,483Feb 22 06:32 PM
Reich KristianChief Scientific OfficerFeb 20 '24Sale57.4310,000574,300100,071Feb 22 06:32 PM
Reich KristianChief Scientific OfficerFeb 21 '24Sale55.3056931,46699,502Feb 22 06:32 PM
Reich KristianChief Scientific OfficerFeb 21 '24Sale55.3150928,1532,986,974Feb 22 06:32 PM
Santos da Silva JorgeChief Executive OfficerFeb 15 '24Sale60.1820,0001,203,6003,147,554Feb 20 06:36 PM
Santos da Silva JorgeChief Executive OfficerFeb 16 '24Sale60.1520,0001,203,0003,127,554Feb 20 06:36 PM
Santos da Silva JorgeChief Executive OfficerFeb 20 '24Sale57.4420,0001,148,8003,107,554Feb 20 06:36 PM
Reich KristianChief Scientific OfficerFeb 14 '24Sale62.4310,000624,300130,071Feb 16 06:02 PM
Reich KristianChief Scientific OfficerFeb 14 '24Sale62.4210,000624,2003,017,483Feb 16 06:02 PM
Reich KristianChief Scientific OfficerFeb 15 '24Sale60.1710,000601,7003,007,483Feb 16 06:02 PM
Reich KristianChief Scientific OfficerFeb 15 '24Sale60.1610,000601,600120,071Feb 16 06:02 PM
Reich KristianChief Scientific OfficerFeb 16 '24Sale60.1510,000601,5002,997,483Feb 16 06:02 PM
Reich KristianChief Scientific OfficerFeb 16 '24Sale60.1510,000601,500110,071Feb 16 06:02 PM
Bodenstedt MatthiasChief Financial OfficerDec 19 '23Sale59.2294,7365,610,266526,167Dec 21 04:01 PM
Bodenstedt MatthiasChief Financial OfficerDec 20 '23Sale58.345,264307,102520,903Dec 21 04:01 PM